#1: Create a post for each bulletin point:
-By the end of this decade, CRISPR gene editing techniques may offer the ability to reverse blinding conditions.
-A medicine called RTH258 is under study as an injectable for macular degeneration, and may greatly increase the interval between injections.
-Genetic therapy may allow a Retinitis Pigmentosa patient’s own skin cells to be genetically corrected and then used to heal that patient’s retina.
-Squalamine, derived from sharks, is being tested as a treatment for macular degeneration. It has been shown to be helpful in retinal vein occlusion and may become useful in diabetic retinopathy.
-From Alzheimer’s to ALS to Multiple Sclerosis to Parkinson’s Disease, preliminary studies indicate retinal findings may contribute to diagnosis and staging. The retina is brain tissue and a growing window to brain disorders.
-MDM2 inhibitors are under study as a potential new treatment for wet macular degeneration that eliminate the need for repeat injections (click to read more).
-Aspirin use as it relates to the eye is complex: it may increase risk in typical macular degeneration, benefit visual outcomes in other retinal disease, and has been shown not to affect diabetic hemorrhages.
-HIV medicines may be effective against macular degeneration.
-Our high density macular microperimetry and highly sensitive electroretinography technologies are capable of detecting subclinical retinal decline before major vision loss to allow prevention.
-Our low duty cycle yellow micropulse laser technology allows the benefits of early treatment in a manner safer than traditional laser.
-Targeted genetic therapy shows promising preliminary human trials in reversing choroideremia, a macular degeneration type disorder.
-PDGFR-beta antibody (an inhibitor of Platelet Derived Growth Factor beta) has long been on the radar as a potential treatment for wet macular degeneration. Now the maker of Eylea has teamed with Bayer in an attempt to bring an Eylea/PDGFR-beta combination to market. Stay tuned for updates. If successful, the benefit may extend beyond macular degeneration to diabetics and vein occlusion patients as well as others.
-Derived from early stem cell research, new treatments may introduce regenerative factors to rejuvenate currently ailing retinal cells without requiring true stem cell transplantation.
-There is good reason to be patient for the perfection of true stem cell applications (click to proceed to the link).
-The first retinal prosthesis to gain FDA approval is the ARGUS II Retinal Prosthesis System. Though currently it has limited uses, it brings great hope to those with severe retinal disease.
-Eylea (aflibercept) has now been approved for use in diabetics. It has been very successful for macular degeneration and retinal vein occlusions.
-Concerned about your genetic risk for macular degeneration? Testing is available at THE RETINA INSTITUTE.
-For diabetics, regular follow up and treatment by retinal eye doctors are proven to save vision. Conversely, lack of examination can lead to unnecessary vision loss.
-High blood pressure (Hypertension) can cause serious vision loss: baseline blood pressure as well as spiking blood pressures from stress or sleep apnea can contribute to vision loss.
-Floaters and flashes can signal retinal detachments.
-Blurry vision can be much more than a need for glasses. A retinal exam can rule out or treat true eye disease.
#2: Refer to Dr. Ebrahim’s original site: http://theretinainstitute.org/_index.php for bulletin points. Make sure each post has a link to each article. For example, “By the end of this decade, CRISPR gene editing techniques may offer the ability to reverse blinding conditions.” creates a new tab and links to https://www.engadget.com/2016/06/22/crispr-gene-editing-approved-for-first-human-trials/
Add this as a button or link on the post page.
Please talk to me if you have questions regarding this ticket.
email completed.
Leave a Comment: